University of Melbourne
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Masters, Colin
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34

Download Options